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Research in context 
Evidence before this study  
We searched MEDLINE and SCOPUS databases up to November 17, 2018, without language 
or any other restrictions, for randomized controlled trials on the utility of ultrasonography in 
enhancing the thrombolytic activity of tPA and found six small scale (phase II) randomized 
clinical trials (RCTs) comparing sonothrombolysis to intravenous tissue plasminogen activator 
(tPA) or conventional treatment. However, no large scale (phase III) RCT using an operator-
independent transcranial ultrasound device delivering sonothrombolysis has been 
performed to date.  
Added value of the study 
Exposure of acute ischemic stroke patients to low-power ultrasound using an operator-
independent device was found to be feasible and likely safe, but with no three-month clinical 
benefit. 
Implications of all available evidence 
Sonothrombolysis with high-frequency ultrasound appears to be safe but offers no clinical 
benefit in acute ischemic stroke patients. The potential efficacy of sonothrombolysis may be 
further investigated in stroke centers that are dependent on patient transfer for 
endovascular reperfusion therapies, or in countries where these therapies cannot yet be 
offered as standard of care. 
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Abstract 
Background: Pulsed-wave ultrasound increases exposure of intracranial thrombus to tissue-
plasminogen-activator (tPA) thereby potentially facilitating early reperfusion. We sought to 
determine if a novel operator-independent transcranial ultrasound device delivering 
sonothrombolysis improves functional outcome after acute ischemic stroke (AIS). 
Methods: We performed a double-blind, multicenter, phase III randomized-controlled 
clinical trial between August 2013 and April 2015, in 76 medical centers in North America, 
Europe and Australasia. We included patients with acute ischaemic stroke (National 
Institutes of Health Stroke Scale scores ≥10) who were eligible for intravenous thrombolysis 
within a 4.5-hour treatment window worldwide and within a 3-hour treatment window in 
North America. After receiving standard of care treatment, including full dose intravenous 
tPA, participants were randomly assigned 1:1, via an interactive web randomization system, 
to 2 h of 2-MHz pulsed-wave ultrasound (intervention group) or sham treatment (control 
group) using an operator-independent device, which had to be activated within 30 min of 
the tPA-bolus. Participants, investigators, and those assessing outcomes were blinded to 
group assignment. The primary outcome was the adjusted improvement in three-month 
modified Rankin Scale (mRS) scores analyzed using ordinal logistic regression as a common 
odds ratio (cOR, shift analysis) in the intention-to-treat population.  
Findings: The trial was stopped early by the study sponsor after the second interim analysis 
due to futility. We randomized 335 patients to the intervention group and 341 patients to 
the control group. The adjusted cOR for 1-point improvement in mRS-score in the 
intervention group (compared to the control group) was 1.05 (95%CI: 0.77-1.45) for patients 
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treated with tPA within 0-3h. There was no strong evidence to indicate a difference between 
groups in the adjusted analyses of three-month mortality (OR=1.19, 95%CI: 0.74-1.92), sICH 
(OR=1.39, 95%CI: 0.51-3.95), brain herniation (OR=2.09, 95%CI: 0.73-6.87), ICH (OR=1.78, 
95%CI: 0.98-3.31), or cerebral edema (OR=2.15, 95%CI: 0.93-5.40).  
Interpretation: Exposure of AIS patients treated with tPA to low-power and high-frequency 
ultrasound using an operator-independent device was feasible and likely safe, but with no 
three-month clinical benefit. The potential efficacy of sonothrombolysis may be further 
investigated in RCTs conducted in stroke centers that are dependent on patient transfer for 
endovascular reperfusion therapies, or in countries where these therapies cannot yet be 
offered as standard of care. 
Funding: Cerevast Therapeutics 
Trial Registration: CLOTBUST-ER, NCT01098981,https://clinicaltrials.gov/ct2/show/NCT01098981  
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TEXT 
Introduction  
Intravenous recombinant tissue plasminogen activator (tPA) is the only approved 
medical reperfusion treatment for acute ischemic stroke (AIS),1,2 and should be initiated as 
early as possible for maximum benefit.3 Yet, half of patients remain disabled or die despite 
medical treatment, due to the initial severity of ischemic insult and inadequate response to 
intravenous thrombolysis (IVT).4,5 Therefore, amplification of tPA effectiveness in thrombus 
dissolution remains an important goal in future development of more effective medical 
stroke therapies even in the era of mechanical thrombectomy, since endovascular 
reperfusion therapies are not readily available in the majority of stroke centers across the 
world.6 
A phase II randomized-controlled clinical trial7 (RCT) of 2-MHz diagnostic ultrasound 
equipment (transcranial Doppler) and meta-analyses8,9 of other similar studies showed that 
ultrasound aimed at the residual flow/thrombus interface can at least double the chance of 
early recanalization. Sonothrombolysis was also associated with a higher likelihood of 
favorable functional outcome in the subgroup of patients with pretreatment National 
Institutes of Health Stroke Scale (NIHSS) scores ≥10 points.10 However, a major obstacle for 
emergency physicians, neurologists and health professionals limiting the use of diagnostic 
ultrasound epuipment in AIS is its operator dependency.11 Therefore, we had previously 
developed a novel “hands-free” therapeutic device with operator-independent targeting of 
the intracranial vessels, tested it in early phase clinical studies, and have demonstrated the 
safety of this technology in humans.12,13   
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Based on our previous work, we undertook a phase III RCT of sonothrombolysis in 
AIS. Our objective was to determine the safety and therapeutic efficacy of our operator-
independent device in combination with intravenous tPA to improve functional outcome, 
compared to intravenous tPA alone in patients with AIS presenting within 3 hours (h) from 
symptom onset. 
Methods 
Study design 
The Combined Lysis of Thrombus using Ultrasound and Systemic tPA for Emergent 
Revascularization (CLOTBUST-ER) was a multinational, double-blind, sham-controlled RCT. 
Details of the methods used in the trial have been published.14 In brief the study was 
performed in 76 institutions and 14 countries. The study was conducted and reported with 
fidelity to the study protocol, available with the full text of this article as an online 
supplement. The trial was approved by the institutional review board at each site or national 
ethics committee, as required.  
 
Participants 
We enrolled AIS patients aged 18-80 years with baseline NIHSS scores of ≥10 points who 
received intravenous tPA within a 4.5-hour treatment window worldwide and within a 3-
hour treatment window in North America as per national approval labels.14 The cut-off of 10 
points in NIHSS-score was selected based on sensitivity analysis of our earlier phase II trial 
indicating that the beneficial effect of sonothrombolysis was amplified in the subgroups of 
acute ischemic stroke patients with NIHSS-scores of ≥10 points.10,14 All subjects were 
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independently functioning in the community immediately prior to their stroke [pre-morbid 
modified Rankin scale (mRS) score 0-1]. Patients were included irrespectively of the 
anticipated stroke localization (anterior or posterior circulation). Written informed consent 
was obtained from the patient or a legal representative before enrolment. A detailed list of 
inclusion and exclusion (including planned endovascular reperfusion procedures) criteria has 
been published14 and are available in the Supplementary Appendix.  
 
Randomization and masking 
Subjects were randomized 1:1, using web-based central randomization14 and random 
permuted blocks stratified by site (random block size of 2, 4, or 6), to active ultrasound+tPA 
(intervention group) or to sham ultrasound+tPA (control group). Each subject was assigned a 
unique, site-specific, identification number after signing the informed consent. Patients were 
randomized either prior or subsequent to administration of the tPA bolus with device to be 
activated within 30 min of tPA bolus. Headframes were programmed based on a 
randomization code that maintained blinding of treating physicians, patients and the sponsor 
to active vs. sham assignments. Randomization was performed (IWRS) provided through IT 
Clinical, Portugal. The system was audited and met all required good clinical practice 
compliance requirements. Blinding was ascertained through an algorithm that determined 
whether "A" setting delivers active insonation and "B" delivers Sham (placebo) insonation, or 
the reverse. The IWRS system was programmed to mask the A or B assignments, therefore 
no user could see which assignment subjects were given. The success of masking procedures 
was not assessed. 
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Procedures 
All eligible subjects received standard of care treatment including full dose intravenous tPA 
(0.9 mg/kg; 90 mg maximum; 10% bolus followed by 90% IV infusion over 60 minutes).  
The headframe had to be placed on all subjects prior to or shortly after tPA-bolus (in order 
not to delay IVT administration), and had to be activated within 30 minutes of tPA-bolus to 
achieve maximum overlap between exposure to the device and tPA infusion. All subjects 
regardless of device activation time were required to wear the headframe for a total of 120 
minutes. Devices were equipped with a timer showing completion of 120 min exposure, and 
a pause button in case the patient had to have repeat CT scan performed as standard of 
care. Interruption time to deliver standard of care procedures requiring temporary device 
removal could not exceed 15 min. A training video was created prior to study initiation. All 
site investigators watched training video and practiced in assembling and placement of 
devices under direct supervision of trained clinical monitors for each country. All sites were 
trained prior to site initiation. In addition, all new investigators were required to undergo 
similar training during the trial. Finally, all global and local investigators meetings had 
training sessions for new and existing sites. 
 
In accordance with parameters mandated by the FDA for currently approved and marketed 
transcranial Doppler (TCD) diagnostic ultrasound devices,15 the intervention group received 
standard of care 2 MHz pulsed-wave transcranial ultrasound for 120 minutes (total average 
power 32Mw; maximum Spatial Peak Temporal Average Intensity: 207Mw/cm2; PRF: 8.3kHz; 
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Pulse duration: 5μS). The control group received sham (inactive) ultrasound for 120 minutes. 
A detailed description of the operator-independent device, vessel targeting without imaging 
or Doppler echo-location, safety testing and phase II functional outcomes data has been 
previously published.12,13  
 
Investigators obtained NIHSS scores pre-treatment, 2h, 24h, on day 7 or at discharge 
(from an acute facility to home), and at day 90; mRS-scores were recorded at day 7 or at 
discharge (if the patient was discharged earlier than day 7) and at day 90.  Significant 
neurological worsening, defined as a total NIHSS score increase by ≥ 4 points from the best 
score at any time during the first 24h post tPA-bolus, required a non-contrast CT to rule out 
symptomatic intracranial hemorrhage (sICH). Routine post-stroke imaging was not 
mandatory but was conducted at all participating centers as standard of care for AIS 
management.  
Outcomes 
The primary outcome is the cumulative ordinal logistic regression analysis of mRS-
scores at 90±10 days from randomization, for all participants enrolled within 3 h of onset of 
stroke symptoms (according to the US Food & Drug Administration regulatory requirements). 
This analysis was repeated as a secondary analysis for all patients who were enrolled within 
4.5h (Global outcome).14 
Other secondary efficacy endpoints included dichotomous mRS 0–1 and mRS 0–2 
rates at day 90, Dramatic Clinical Recovery at 2h, Clinical Recovery at 24h, Clinical Recovery 
at day 90, Neurological Improvement at 24h, Neurologic Worsening at 24h, Length of Stay, 
 13 
Sliding Dichotomy Independent Functional Outcome at Day 90, NIHSS at 2h, NIHSS at 24h, 
NIHSS at day 7, NIHSS at day 90 and mRS at day 7.14 Dramatic clinical recovery assessed at 
120±15 min after headframe activation included a reduction of 10 or more points in NIHSS 
compared with pretreatment, or a total NIHSS score of 3 or less.14 Clinical recovery assessed 
at 24±2 h after headframe activation included a reduction of 10 or more points on NIHSS 
compared with pretreatment, or a total NIHSS score of 3 or less.14 Neurological improvement 
assessed at 24±2 h after headframe activation required a reduction of 5 or more points on 
NIHSS compared with the pretreatment score.14 Neurological worsening assessed at 24±2 h 
after headframe activation required an increase of 4 or more points on NIHSS compared with 
the pretreatment score.14 Independent functional outcome adjusting for pretreatment NIHSS 
assessed at 90±10 days included mRS score 0–1 for subjects with pretreatment NIHSS 10–14, 
and mRS score 0–2 for subjects with pretreatment NIHSS>14.14 
Safety outcomes included the proportion of subjects in the intervention vs. control 
group experiencing sICH within 24h of tPA-bolus and an overall analysis of adverse events as 
previously described.14 Symptomatic ICH per study protocol (online supplement) was defined 
as neurological deterioration (≥4 points worsening on the NIHSS compared with the best 
prior examination) within 24h after tPA bolus with documented parenchymal hemorrhage 
type 2 or remote parenchymal hemorrhage type 2.14 All intracranial bleeds within 24h which 
were associated with neurological deterioration as defined above were sent to a central 
imaging core lab for independent adjudication. To allow comparison of sICH rates to the 
recently adopted 36h time window,17 the above mentioned sICH definition and adjudication 
process were also applied to all neurological deteriorations reported within 36h post tPA 
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bolus.1 Three sICH cases were diagnosed by the local investigators without central 
adjudication due to early trial termination by the sponsor. However, we included these cases 
in the final sICH group assuming the worst case scenario. All intracranial hemorrhages which 
were not associated with neurological deterioration of 4 or more points on the NIHSS scale 
were subsequently classified as asymptomatic intracranial hemorrhages. 
All cases of pre-specified adverse events were reported by the blinded clinical 
investigators of the participating centers. These events were reviewed and adjudicated by a 
blinded independent adjudication panel within the DSMB. In the event of a discrepancy 
between the adjudication panel and the clinical investigator, the adjudication panel 
determination was final. Brain herniation, cerebral oedema and midline shift were not pre-
specified adverse events of our study and there were not centrally adjudicated. Information 
on these adverse events was collected based on the onsite clinical and radiology reports. 
There was no standardized definition for these adverse events. All adverse events were 
coded and tabulated by MedDRA System Organ Class and presented in descending 
frequency. Adverse events were also tabulated by severity and relationship to the 
investigational device.14 Death from any cause within 90 days of treatment and the 
proportion of subjects who died due to adverse events were also summarized by treatment 
group.14 
Statistical analysis 
Details on our pre-planned statistical analysis plan, power estimations and planned 
interim analyses have been published previously,14 and are also available in the Appendix. 
Interim analyses assessing the primary outcome between treatment groups were scheduled 
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after approximately one-third and two-thirds of 90-day mRS outcomes becoming available. 
Using O’Brien-Fleming boundaries for the group sequential design with 90% power and 
testing at approximately one-third and two-thirds of the subjects imply critical values of P = 
0.0003525 and P = 0.0120085 at the first and second interim analyses, respectively, and P = 
0.0462386 at the final analysis. In addition, a conditional power futility analysis was 
scheduled to be performed at each of the interim analysis point by the DSMB, where the 
study would stop should the conditional power fall below 15%. 
Analyses reported here were performed in the intention-to-treat population (by PM 
and TAK) using a program written in Matlab© (version R2018b) and a single ‘Master’ data 
file was generated. All further statistical analyses were performed in R (version 3.4) running 
under an R Studio environment and primary outcomes were cross-checked in Matlab 
environment. The plans of all statistical analyses were performed prior to the unblinding of 
the data.  
Primary outcome was specified as the proportional odds logistic regression (polr 
command in R) over the 90-day mRS distribution after collapsing grades 5 and 6.14 By doing 
univariate logistic regressions for each of the five groupings we observed that the odds ratios 
bump around one with negligible differences attributed to random variation, giving credit to 
the hypothesis of proportional odds across the groupings of the mRS. Additionally, we 
conducted two imputation analyses on the primary endpoint (US outcome). The missing 
mRS-score values were estimated using multiple imputation methodology18 in the first 
analysis based on the strongest predictors of 90 day mRS-score as pre-specified in our 
statistical analysis protocol14 (baseline NIHSS, 24 hour NIHSS and day 7/discharge mRS along 
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with assignment to treatment or control). The missing mRS-score values were imputed to 
the worst case (e.g. mRS-score of 6) in the second analysis. 
Unadjusted and adjusted analyses are reported separately. Both unadjusted and 
adjusted statistical analyses for secondary endpoints were pre-specified. The unadjusted 
approach was the primary analytic approach, while the adjusted approach served as a 
secondary analysis. Pre-specified secondary outcomes14 were tested in the unadjusted 
analyses with Fisher’s two-sided test of proportion and confidence intervals were provided 
according to the methodology of Bland and Altman.19 Pre-specified safety outcomes14 were 
also tested using Fisher’s two-sided test of proportions. Adjustment was done in terms of 
baseline NIHSS, age, baseline serum glucose, and time to tPA-bolus. These factors were 
chosen post-hoc by the steering committee prior to unblinding of the data. Adjustment for 
these factors was applied uniformly for all efficacy and safety outcomes. In all analyses no 
allowance for multiplicity was made. To allow for the interim analyses alpha spend 
adjustment was not done while calculating the p-values in all analyses. Also, the point 
estimates were naïve and not bias adjusted for the interim analyses.  
 
Role of the funding source 
 The trial was funded by Cerevast Therapeutics and designed and led by a Steering 
Committee that included academic investigators and representatives of the sponsor. The site 
investigators gathered the data, with monitoring and database maintenance performed by 
the sponsor. The first and subsequent drafts of the manuscript were written by AVA and GT 
incorporating input from all the authors. The academic authors had unrestricted access to 
 17 
the data, performed the data analysis with the primary and the independent statisticians, 
and attest to the integrity of the trial and the completeness and accuracy of the reported 
data. The trial was monitored by an independent Data and Safety Monitoring Board 
(Supplementary Appendix). The study sponsor had no involvement in the manuscript 
preparation, including data analysis and text drafting. The steering committee of CLOTBUST-
ER had the final responsibility for reaching the decision to submit for publication. 
 
Results  
A total of 676 participants underwent randomization (335 to the intervention group 
and 341 to the control group). Patients were enrolled at 76 medical centers between August 
2013 and April 2015 in North America (n=30), Europe (n=39) and Australasia (n=7). Details 
regarding the individual centers that enrolled patients in CLOTBUST-ER are available in the 
Supplementary Appendix. Intervention and control groups of the intention to treat 
population did not differ in any of the baseline characteristics (Table 1). The median elapsed 
time from tPA bolus to headframe activation was similar in the intervention (20min; 
interquartile range: 13-27) and control group (20 min; interquartile range: 13-25). Values on 
mean systolic blood pressure levels before tPA-bolus were missing in 9 and 13 patients in the 
intervention and control groups, respectively, while values on mean diastolic blood pressure 
before tPA-bolus were unavailable in 8 and 13 patients in the intervention and control 
groups, respectively. The CONSORT flow diagram is presented in Figure 1. 
Primary outcome 
CLOTBUST-ER was stopped early for futility after the per protocol defined second 
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interim analysis, having the two-thirds of 90-day mRS outcomes available, from the DSMB 
according to pre-specified stopping rules. The results of the first and second interim analysis 
on the primary outcome of interest are available in eFigure 1, appendix. Subjects who were 
enrolled in the study at the time of the futility determination were followed until 90 days 
post-tPA administration by the site investigators despite discontinuation of the study by the 
study sponsor. We therefore describe the results in the total sample of patients randomized 
in CLOTBUST-ER. 
There were 28 and 35 patients with missing data on three-month mRS-scores in the 
intervention and the control arms respectively. Patients with missing follow-up data were 
censored from the analyses of the primary endpoint and the secondary endpoints that were 
evaluated at 90 days following symptom onset. The two groups did not differ in terms of the 
primary US outcome [adjusted common odds ratio (cOR): 1.05; 95%CI: 0.77-1.45; Table 2 & 
Figure 2]. Additionally, the primary Global outcome did not differ between the two groups 
(adjusted cOR: 1.06; 95%CI: 0.80-1.42; Table 2 & eFigure 2, appendix). We also detected no 
difference between groups on the primary outcome of interest (primary US outcome), after 
adjusting for the per-protocol defined covariates (site, baseline NIHSS, pre-morbid mRS and 
age) in the statistical analysis plan (adjusted cOR: 0.93, 95%CI: 0.69-1.24). In addition, there 
was no difference in the adjusted analyses on the primary outcome of interest (primary US 
outcome) using either multiple imputation methodology (unadjusted OR: 0.98, 95%CI: 0.73-
1.31; adjusted OR: 0.99, 95%CI: 0.74-1.34; eTable 1) or imputation to the worst case 
(unadjusted OR: 1.08, 95%CI: 0.80-1.45; adjusted OR: 1.14, 95%CI: 0.84-1.54; eTable 2). 
Secondary efficacy outcomes 
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  All secondary outcomes are shown in Table 2. The two groups did not differ in any of 
the secondary outcomes. The adjusted ORs for patients randomized within 3 hours were 
1.27 (95%CI: 0.85-1.89) for functional independence, 0.99 (95%CI:0.65-1.52) for dramatic 
clinical recovery at 2 h, 0.79 (95%CI:0.54-1.15) for clinical recovery at 24 h, 1.04 (95%CI:0.73-
1.49) for neurological improvement at 24h and 1.37 (95%CI:0.70-2.71) for neurologic 
deterioration at 24h. 
Safety outcomes 
 The safety outcomes in the safety population are shown in Table 3. The rates of 
death (16.7% vs. 13.4%, OR: 1.23, 95%CI: 0.79-1.90) and serious adverse events (26.2% vs. 
24.0%, OR: 1.12, 95%CI: 0.79-1.60) were similar in the two groups. The rates of sICH were 
2.8% and 2.1% in intervention and control groups respectively (OR: 1.34; 95%CI: 0.49-3.65). 
The two groups did not differ in any of the safety outcomes with the exception of 
asymptomatic hemorrhage (10.7% vs 6.1%; OR: 1.86, 95%CI: 1.04-3.30); this association did 
not retain statistical significance in adjusted analyses (OR for asymptomatic intracranial 
hemorrhage: 1.78, 95%CI: 0.98-3.31). The only adverse event that differed between the two 
groups was atrial fibrillation (8.8% in intervention vs. 4.2% in control groups, OR: 2.18, 
95%CI: 1.12-4.22). However, after excluding patients with atrial fibrillation at baseline 
assessment, this difference did not retain statistical significance (7.3% vs. 4.0%; OR: 1.90 
0.95-3.82). The occurrence of partial seizures was 0% (n=0) and 0.6% (n=2) in the control and 
intervention groups respectively (OR: 5.22, 95%CI: 0.25-109.20).  
Subgroup and sensitivity analyses 
 We did not detect any significant differences (p value for interaction ≥0.1) in the 
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effect of sonothrombolysis in pre-specified subgroup analyses by sex, age, baseline stroke 
severity and onset to treatment time (Figure 3). Sensitivity analyses failed to detect any 
difference in primary and secondary efficacy outcomes, mortality and sICH after removing 
subjects with ascertainment of three-month mRS-scores following the completion of the 
second interim analysis (47 & 52 in the intervention and control groups respectively). Further 
details on sensitivity analyses are available in the appendix. The analyses of efficacy 
outcomes in the per-protocol and safety populations (eTable 3 & eTable 4, appendix) yielded 
similar results to the respective analyses in the intention-to-treat population (Table 2 & 
eFigure 3). Similarly, the analyses of safety outcomes yielded almost identical results in the 
intention-to-treat (eTable 5), per protocol (eTable 6) and safety (Table 3) populations. 
 
Discussion 
CLOTBUST-ER was stopped early due to futility, according to pre-specified rules and 
failed to show an additional benefit in functional outcome with sonothrombolysis using a 
novel operator-independent ultrasound device as compared with the standard therapy of 
IVT alone. However, the results of our trial indicate the potential feasibility and safety of 
exposure of AIS patients treated with IVT to high-frequency (low-power) ultrasound using an 
operator-independent device.  
 Our findings regarding sonothrombolysis safety corroborate the conclusions of two 
independent meta-analyses suggesting the potential safety of high-frequency ultrasound 
coupled with IVT as an investigational reperfusion therapy for AIS.8,9 The sICH rate (2.8%) in 
the intervention group of CLOTBUST-ER is less than the pooled sICH rate of previous smaller 
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RCTs of sonothrombolysis (3.8%).8 It is also comparable to the rate of European Cooperative 
Acute Stroke Study III2 (2.4%) and the Safe Implementation of Thrombolysis in Stroke-
Monitoring Study16 (1.7%), while being lower than the sICH rate (3.7%) reported in an 
individual patient data meta-analysis of 9 IVT trials20, despite the fact that pre-treatment 
stroke severity was higher in our trial.  
 A potential safety concern that needs to be addressed is the higher rate of cerebral 
edema, brain herniation and asymptomatic ICH detected in the sonothrombolysis group in 
the unadjusted analyses. These adverse events were reported on the basis of radiology 
reports by local investigators without being subjected to central adjudication. Previous RCTs 
failed to detect any association between ultrasound-enhanced thrombolysis and risk of 
cerebral edema.7,21,22 Likewise, contrary to sICH asymptomatic ICH is not related to clinical 
outcome in patients treated with intravenous thrombolysis.23 Moreover, the rates of midline 
shift were practically identical in the two groups of CLOTBUST-ER (2.7% & 2.6%), while no 
difference was noted in the rates of neurological deterioration at 24h. Finally, the 
associations of sonothrombolysis with cerebral edema, brain herniation or asymptomatic ICH 
were not significant after adjustment for pre-specified confounders. Nevertheless, the 
potential relationship between 2-MHz frequency sonothrombolysis and cerebral edema 
deserves further exploration in future RCTs with central adjudication of brain herniation. 
Sonothrombolysis did not improve functional outcome in CLOTBUST-ER. This may be 
partially explained by certain design features and study limitations. First, unlike previous 
studies of ultrasound-enhanced thrombolysis requiring imaging documentation of proximal 
intracranial occlusions,7,21,22 stroke severity was used as the surrogate measure of large 
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vessel occlusion and vascular imaging was not mandatory in our trial. Consequently, some of 
our patients might not have had a proximal occlusion within the target area of our operator-
independent device. We speculate that our findings parallel the results of the Interventional 
Management of Stroke III (IMS III) trial24 that confirmed the need to select patients with 
proximal arterial occlusions using vessel imaging to test acute reperfusion therapies (instead 
of enrolling those with severe stroke as surrogate for an occlusion).  
Second, compared to a hand-held device as used in previous positive studies,7,8 it is 
possible that our operator-independent device provided less direct thrombus exposure to 
ultrasound as a result of multi-transducer headframe design.25,26 Third, data on functional 
outcome at three months were unavailable in 63 patients (9% of the study population) due 
to the early discontinuation of CLOTBUST-ER following the second interim analysis by the 
study sponsor. After the study termination, three-month follow-up evaluations were 
completed in the majority of cases due to the tremendous efforts of onsite investigators who 
were asked to complete the trial at their own time and efforts. Nevertheless, it should be 
noted that our sensitivity analysis indicated that there was no difference in efficacy and 
safety outcomes after exclusion of subjects with documentation of their three-month 
functional status following the second interim analysis. Furthermore, we formally tested and 
verified the randomness of the missing follow-up data in exploratory analyses. Fourth, 
potential enrollment bias at certain sites arising from higher priority given to endovascular 
treatment options might have led to enrollment of fewer large vessel occlusions at those 
centers.  
Our study has limitations such as lack of pre-treatment visualization of a proximal 
 23 
intracranial arterial occlusion, substantial number of incomplete three-month follow up 
evaluations (9% of enrolled patients), non-significant difference in onset-to-treatment times 
in favor of the intervention group (117 vs. 126 min) and reliance on investigator ability to 
properly mount the device and gel pads, without any further on-site validation being carried 
out. We should also highlight the lack of prospectively collected data on the ischemic stroke 
etiologic classification or anatomic localization, and therefore the inability to perform 
additional subgroup analyses for patients with lacunar vs. non-lacunar strokes and patients 
with anterior vs. posterior circulation strokes.  
Moreover, only a limited number of patients (n=38) was enrolled in the designed 
arterial recanalization substudy [based on pre- and post-treatment CT angiography (CTA)] 
and we were unable evaluate the effect of sonothrombolysis on recanalization and 
functional outcomes of AIS patients with large vessel occlusions. The steering committee 
decided not to make vascular imaging mandatory for patient inclusion given the participation 
of centers with unavailable CT angiography on a 24/7 basis and since 24/7 CTA was not 
standard of care at the time of study design. Moreover, we decided to implement a similar 
approach to IMS III Trial24 to identify patients with large vessel occlusions using a cut-off of 
10 points or greater in NIHSS-score. Unfortunately, the negative results of IMS III could not 
be predicted during CLOTBUST-ER design and initiation. However, we acknowledge the lack 
of pre-treatment visualization of a proximal intracranial arterial occlusion in the vast majority 
of our population as a major study limitation.  
After taking also into account the positive results of recent thrombectomy trials 
(highlighting CT angiography as standard of care), we have re-designed the operator-
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independent ultrasound device to target CTA-located large vessel occlusions with only one 
set of transducers that will be placed over the right or left temporal window or suboccipitally 
dependently on occlusion location seen on CTA. The re-designed device will also use novel 
coupling gel pads to achieve improved headframe fixation during insonation. This new device 
will be tested in the recently launched TRUST trial (NCT 03519737),27 in which all patients 
with large vessel occlusions who meet standard tPA criteria and are being transferred from 
primary to comprehensive stroke centers (“drip-n-ship”) will be randomized to ultrasound or 
no ultrasound with primary end-point being recanalization at receiving hospitals on digital 
subtraction angiography prior to thrombectomy. Finally, it should be mentioned that the 
study was terminated by the sponsor and no additional funding was available beyond 
completion of follow-ups of enrolled patients. The lengthy process of manuscript 
preparation was the main reason for delaying publication of the study findings that were 
partially presented in European Stroke Organization Conference 2016 in Barcelona. 
In conclusion, exposure of stroke patients treated with tPA to low-power ultrasound 
delivered by a novel operator-independent device was feasible and likely safe with no overall 
significant clinical benefit at 90 days. Our experience in CLOTBUST-ER indicates that the 
increasing implementation of endovascular therapies across major academic stroke centers 
raises significant challenges for clinical trials aiming to test non-interventional or adjuvant 
reperfusion strategies. The potential efficacy of sonothrombolysis may be further 
investigated in RCTs conducted in stroke centers that are dependent on patient transfer for 
endovascular reperfusion therapies, or in countries where these therapies cannot yet be 
offered as standard of care. Given that a more targeted approach of sonothrombolysis based 
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on pre-treatment CTA may have a potential therapeutic effect and utility in the “drip and 
ship paradigm”, a newly designed ultrasound device to deliver ultrasound to primary region 
of occlusion will be assessed in a forthcoming phase 3 RCT.27  
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Figure 1: Trial profile 
 
 
Figure 2: Modified Rankin Scale Scores at 90 Days in patients treated with intravenous 
thrombolysis within 3 h 
Analysis is in the Intention-to-Treat Population. Scores on the modified Rankin scale range 
from 0 to 6, with 0 indicating no symptoms, 1 no clinically significant disability, 2 slight 
disability (patient is able to look after own affairs without assistance but is unable to carry 
out all previous activities), 3 moderate disability (patient requires some help but is able to 
walk unassisted), 4 moderately severe disability (patient is unable to attend to bodily needs 
without assistance and unable to walk unassisted), 5 severe disability (patient requires 
constant nursing care and attention), and 6 death.  
 
Figure 3: Common odds ratio for improvement on the modified Rankin scale at 90 days in 
patients treated with intravenous thrombolysis within 4.5 h 
Data analyzed according to ordinal logistic regression after collapsing mRS scores 5 and 6 and 
adjusting for  age, NIHSS score at baseline; time from stroke onset to tPA (tissue 
plasminogen activator) bolus and baseline serum glucose across the different prespecified 
subgroups. The thresholds for age and National Institutes of Health Stroke Scale (NIHSS) 
score (range, 0 to 42, with higher scores indicating more severe neurologic deficits) were 
chosen at the median. The threshold for time from stroke onset to tPA (tissue plasminogen 
activator) bolus was pre-specified. 
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Tables 
Table 1. Baseline characteristics of the study population (intention to treat analysis). 
 
Variables Intervention 
(n=335) 
Control 
(n=341) 
Mean age±SD, years 67.0±10.6 66.7±10.6 
Male sex, no (%) 187 (55.8%) 206 (60.4%) 
Median NIHSS-score (IQR), points 15 (11-18) 14 (11-18) 
Hypertension, no (%) 196 (58.5%) 213 (62.5%) 
Diabetes mellitus, no (%) 75 (22.4%) 80 (23.5%) 
Atrial fibrillation, no (%) 62 (18.5%) 54 (15.8%) 
Pre-stroke modified Rankin Scale score 0-1, no (%) 334 (99.7) 339 (99.4) 
Mean systolic blood pressure before tPA-bolus±SD, 
mmHg*  
150.3±20.2 150.3+20.4 
Mean diastolic blood pressure before tPA-bolus±SD, 
mmHg**  
81.7±13.2 81.8±13.2 
Mean serum glucose before tPA-bolus±SD, mg/dL 139.6±53.0 137.5±53.4 
Median time from symptom onset to tPA bolus (IQR), min 117 (95-156) 126 (96-165) 
Time from symptom onset to tPA bolus within 3 h, no (%) 279 (83.3%) 285 (83.6%) 
Median time from symptom onset to headframe activation 
(IQR), min 
136 (117-175) 148 (115-
185.5) 
Mean Time from IV rtPA bolus to Head Frame Activation ± 
SD, min 
20.6 ±9.7 19.7±10.3 
Median Time from IV rtPA bolus to Head Frame Activation 
(IQR) min 
20 (13-27) 20 (13-25) 
Race   
  White 261 270 
  Black/African-American 18 17 
  Hispanic-Latino 37 33 
  Asian 12 13 
  South-Asian/Indian 0 1 
  Filipino 0 1 
  American-Indian/Alaskan Native 0 2 
  Unknown 7 4 
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Table 2. Primary and secondary efficacy outcomes in the intention-to-treat population (335 & 341 
patients in the intervention & control groups). A total of 297 and 296 patients from the intervention 
and the control groups were included in the analysis of US primary outcome. 
Variables Intervention 
(n=335)  
Control 
(n=341) 
Unadjusted 
OR (95% CI) 
p Adjusted 
OR (95%CI) 
p  
Primary outcome: mRS-score at 90 
days (median, IQR) 
      
  US Primary outcome  3.0 (1.0-4.0) 3.0 (1.0-4.0) 1.03 (0.76-1.40) 0.8440 1.05 (0.77-1.45) 0.7414 
  Global Primary outcome 3.0 (1.0-4.0) 3.0 (1.0-4.0) 1.00 (0.76-1.32) 0.9889 1.06 (0.80-1.42) 0.6732 
Secondary outcomes        
mRS-Score at 7 days or Discharge 
US 
3.0 (2.0-4.0) 4.0 (1.0-5.0) 1.03 (0.76-1.40) 0.8311 1.09 (0.80-1.50) 0.5791 
mRS-Score at 7 days or Discharge 
Global 
3.0 (2.0-4.0) 4.0 (1.0-5.0) 0.99 (0.75-1.31) 0.9698 1.10 (0.82-1.47) 0.5145 
mRS-score at 90 days 0-1; US, no 
(%)  
82 (32.2%) 78 (30.7%) 1.07 (0.73-1.55) 0.7747 1.16 (0.77-1.75) 
 
0.4804 
mRS-score at 90 days 0-1; Global, 
no (%)  
96 (31.3%) 98 (32.0%) 0.97 (0.69-1.36) 0.8624 1.05 (0.73-1.52) 
 
0.7867 
mRS-score at 90 days 0-2; US, no 
(%)  
127 (49.8%) 118 (46.5%) 1.14 (0.81-1.62) 0.4783 1.27 (0.85-1.89) 
 
0.2404 
mRS-score at 90 days 0-2; Global, 
no (%)  
149 (48.5%) 142 (46.4%) 1.09 (0.79-1.50) 0.6278 1.25 (0.87-1.79) 
 
0.2237 
Independent functional outcome at 
90 days; US, no (%) 
96 (37.6%) 93 (36.6%) 1.04 (0.73-1.50) 0.8545 1.11 (0.76-1.63) 
 
0.5768 
Independent functional outcome at 
90 days; Global, no (%) 
113 (36.8%) 114 (37.2%) 0.98 (0.71-1.36) 0.9334 1.07 (0.75-1.51) 
 
0.7178 
Dramatic clinical recovery at 2 h; 
US, no (%)  
58 (21.6%) 60 (21.7%) 0.99 (0.66-1.49) >0.9999 0.99 (0.65-1.52) 
 
0.9735 
Dramatic clinical recovery at 2 h; 
Global, no (%)  
60 (18.6%) 65 (19.7%) 0.93 (0.63-1.37) 0.7656 0.95 (0.63-1.43) 
 
0.8012 
Clinical recovery at 24 h; US, no (%)  83 (31.8%) 102 (37.6%) 0.77 (0.54-1.10) 0.1723 0.79 (0.54-1.15) 
 
0.2222 
Clinical recovery at 24 h; Global, no 
(%)  
100 (31.9%) 116 (36.0%) 0.83 (0.60-1.16) 0.3148 0.88 (0.63-1.24) 
 
0.4649 
Neurological improvement at 24 h; 
US, no (%)  
148 (56.7%) 154 (56.8%) 0.99 (0.71-1.40) >0.9999 1.04 (0.73-1.49) 
 
0.8339 
Neurological improvement at 24 h; 
Global, no (%)  
176 (56.2%) 180 (55.9%) 1.01 (0.74-1.39) 0.9365 1.08 (0.78-1.49) 
 
0.6613 
Neurological deterioration at 24 h; 
US, no (%)  
23 (8.8%) 17 (6.3%) 1.44 (0.75-2.77) 0.3242 1.37 (0.70-2.71) 
 
0.3627 
Neurological deterioration at 24 h; 
Global, no (%)  
29 (9.0%) 19 (6.2%) 1.63 (0.89-2.97) 0.1330 1.47 (0.80-2.75) 
 
0.2162 
NIHSS at Day 7 US (median, IQR) 5 (1-12) 6 (1-12)  0.7951   
NIHSS at Day 7 Global (median, 5 (1-12) 6 (1-12)  0.8167   
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IQR) 
NIHSS at Day 90 US (median, IQR) 2 (0-6) 2 (0-5)  0.8413   
NIHSS at Day 90 Global (median, 
IQR) 
2 (1-6) 2 (1-5)  0.6834   
Duration of hospital stay until 
discharge; US, days (median, IQR)  
7 (5-12) 7 (4-11)  0.6033   
Duration of hospital stay until 
discharge; Global, days (median, 
IQR)  
7 (5-12) 7 (4-11)  0.4772   
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Table 3. Safety outcomes  and serious adverse events within 90 days after randomization in the 
safety population (317 & 329 patients in the intervention & control groups).  
 
Variables Intervention 
(n=317) 
Control 
(n=329) 
OR (95% CI) 
 
P Adjusted OR 
(95%CI) 
P 
Death, no (%) 51 (16.7%) 44 (13.4%) 1.23 (0.79-1.90) 0.3726 1.19 (0.74-1.92) 0.4810 
Death due to serious adverse event, 
no (%) 
34 (10.7%) 34 (10.3%) 1.04 (0.63-1.72) 0.8985 1.00 (0.58-1.73) 0.9962 
Serious adverse events, no (%) 83 (26.2%) 79 (24.0%) 1.12 (0.79-1.60) 0.5268 1.08 (0.74-1.57) 0.6890 
Symptomatic intracranial 
hemorrhage at 24 h, no (%) 
8 (2.5%) 6 (1.8%) 1.39 (0.48-5.06) 0.5974 1.43 (0.49-4.44) 0.5091 
Symptomatic intracranial 
hemorrhage at 36 h, no (%) 
9 (2.8%) 7 (2.1%) 1.34 (0.49-3.65) 0.6192 1.39 (0.51-3.95) 0.5227 
Asymptomatic intracranial 
hemorrhage at 24 h, no (%) 
34 (10.7%) 20 (6.1%) 1.86 (1.04-3.30) 0.0457 1.78 (0.98-3.31) 0.0609 
Cerebral Edema, no (%) 17 (5.8%) 8 (2.4%) 2.27 (0.97-5.35) 0.0660 2.15 (0.93-5.40) 0.0839 
Brain Herniation  11 (3.5%) 5 (1.5%) 2.33 (0.80-6.78) 0.1324 2.09 (0.73-6.87) 0.1877 
Midline Shift 9 (2.8%) 9 2.7%) 1.04 (0.41-2.65) >0.9999 0.98 (0.35-2.72) 0.9664 
Study discontinuation due to 
adverse events, no (%) 
21 (6.6%) 22 (6.7%) 0.99 (0.53-1.84) >0.9999 1.01 (0.53-1.96) 0.9642 
First most common adverse event 
(Headache), n (%) 
57 (18.0%) 50 (15.2%) 1.22 (0.81-1.85) 0.3972 1.30 (0.85-2.00) 0.2275 
Second most common adverse 
event (Pyrexia), n (%) 
30 (9.5%) 37 (11.2%) 0.82 (0.50-1.37) 0.5192 0.81 (0.48-1.36) 0.4325 
Third most common adverse event 
(Nausea), n (%) 
33 (10.4%) 27 (8.2%) 1.30 (0.76-2.22) 0.3461 1.32 (0.77-2.29) 0.3126 
Fourth common adverse event 
(Pneumonia/Aspiration 
Pneumonia), n (%) 
34 (10.7%) 27 (8.2%) 1.34 (0.79-2.28) 0.2848 1.33 (0.76-2.36) 0.3159 
Fifth most common adverse event 
(Constipation), n (%) 
24 (7.6%) 33 (10.0%) 0.73 (0.42-1.27) 0.3315 0.69 (0.39-1.20) 0.1927 
Atrial Fibrillation as adverse event, n 
(%) 
28 (8.8%) 14 (4.3%) 2.18 (1.12-4.22) 0.0245 2.25 (1.17-4.52) 0.0181 
Atrial Fibrillation as adverse event 
after exclusion of patients with 
atrial fibrillation at baseline, n (%) 
23 (7.3%) 13 (4.0%) 1.90 (0.95-3.82) 0.0855 1.91 (0.96-3.97) 0.0722 
 
